Pharma BD Deal Intelligence
Illumina entered into a definitive agreement to acquire GRAIL for cash and stock consideration of $8 billion, consisting of $3.5 billion in cash and…
GRAIL (Nasdaq: GRAL) submitted the final module of its Premarket Approval (PMA) application to the U.S. FDA for the Galleri multi-cancer early detection test…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Illumina acquired GRAIL for approximately $7.1 billion in cash and stock, gaining GRAIL's Galleri multi-cancer early detection blood test. Illumina had originally spun GRAIL out in 2016. The deal was completed despite opposition from the FTC and European Commission; Illumina was ultimately ordered to divest GRAIL in 2023 and completed the divestiture in June 2024.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Illumina, Inc. / GRAIL, Inc. (this deal) | 2020 | $8.0B | 36 |
| Illumina, Inc. / Amgen Inc. | 2020 | — | 56 |
| Illumina, Inc. / GRAIL, Inc. | 2021 | $7.1B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2020 deals · Illumina, Inc. deals · Oncology deals